Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.780
+0.150 (9.20%)
At close: May 6, 2026, 4:00 PM EDT
1.790
+0.010 (0.56%)
After-hours: May 6, 2026, 4:00 PM EDT

Chemomab Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
3.733.417.0811.566.03
Research & Development
5.8311.3318.3816.986.33
Total Operating Expenses
9.5714.7425.4628.5312.37
Operating Income
-9.57-14.74-25.46-28.53-12.37
Total Non-Operating Income (Expense)
0.570.791.240.35-0.11
Pretax Income
-9-13.95-24.22-28.18-12.48
Provision for Income Taxes
----0.53-
Net Income
-9-13.95-24.22-27.65-12.48
Net Income to Common
-9-13.95-24.22-27.65-12.48
Shares Outstanding (Basic)
64333
Shares Outstanding (Diluted)
64333
Shares Change (YoY)
42.10%52.79%3.26%9.70%51.71%
EPS (Basic)
1.443.128.249.684.80
EPS (Diluted)
1.443.128.249.684.80
EPS Growth
-53.85%-62.14%-14.88%101.67%36.36%
Shares Outstanding
7.194.713.5511.052.85
Free Cash Flow
-11.13-15.39-23.61-20.44-12.61
Free Cash Flow Per Share
-1.75-3.43-8.04-7.18-4.86
EBITDA
-9.5-14.69-25.39-28.48-12.33
EBIT
-9.57-14.74-25.46-28.53-12.37
Effective Tax Rate
0.00%0.00%0.00%1.89%0.00%
Updated Mar 20, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q